Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
NCT06957431Phase 1Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2025
- Primary completion
- May 2031
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of zanzalintinib in leiomyosarcoma (LMS), Liposarcoma and liposarcoma (LPS) (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Number of adverse events at 25 months and Maximum tolerated dose / recommended phase II dose at 21 days. Started Oct 2025; status: recruiting.
02
Drugs
zanzalintinib
03
Conditions
leiomyosarcoma (LMS)Liposarcomaliposarcoma (LPS)
Beyond the preview
Go deeper on NCT06957431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957431.